Acute Respiratory Distress Syndrome (ARDS) Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Increasing Demand for Acute Respiratory Distress Syndrome (ARDS) Treatment
   3. Market Restraints
      1. Lack of Skilled Professionals
      2. Increasing Cost of Treatment Therapeutics
   4. Market Opportunities
      1. More Product Launches
   5. Market Trends
      1. Focus on Early Intervention and Prevention
      2. Rise in Collaborative Research and Clinical Trials
5. MARKET SEGMENTATION
   1. By Cause
      1. Coronavirus Disease 2019 (COVID-19)
      2. Sepsis
      3. Inhalation of Harmful Substances
      4. Severe Pneumonia
      5. Others
   2. By Type
      1. Diagnosis
      2. Treatment
   3. By Route of Administration
      1. Oral
      2. Parenteral
      3. Intramuscular
      4. Intravenous
      5. Others
   4. By End User
      1. Hospitals
      2. Specialty Clinics
      3. Home Healthcare
      4. Others
   5. By Distribution Channel
      1. Direct Tender
      2. Hospital Pharmacy
      3. Retail Pharmacy
      4. Online Pharmacy
      5. Others
   6. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Armstrong Medical (U.K.)
      2. Besmed Health Business Corp. (Taiwan)
      3. Bayer AG (Germany)
      4. Drägerwerk AG & Co. KGaA (Germany)
      5. EUROSETS (Italy)
      6. Fisher & Paykel Healthcare Limited (New Zealand)
      7. F. Hoffmann-La Roche Ltd (Switzerland)
      8. Getinge AB. (Sweden)
      9. LivaNova PLC (U.K.)
      10. Novartis AG (Switzerland)
      11. Pfizer Inc. (U.S.)
      12. Sun Pharmaceutical Industries Ltd (India)
      13. Terumo Medical Corporation (U.S.)
      14. WEINMANN Emergency Medical Technology GmbH + Co. KG (Germany)
   2. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global acute respiratory distress syndrome (ARDS)market?

The global market of acute respiratory distress syndrome (ARDS) is projected to reach USD 5.35Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global acute respiratory distress syndrome (ARDS)market?

The global acute respiratory distress syndrome (ARDS) market has an estimated annual growth rate of 5.6%. 

Q.3. What are the recent trends of acute respiratory distress syndrome (ARDS)market?

Focus on early intervention and prevention and rise in collaborative research and clinical trials are some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in acute respiratory distress syndrome (ARDS)?

The major companies profiled in this report include Armstrong Medical (U.K.), Besmed Health Business Corp. (Taiwan), Bayer AG (Germany), Drägerwerk AG & Co. KGaA (Germany), EUROSETS (Italy), Fisher & Paykel Healthcare Limited (New Zealand), F. Hoffmann-La Roche Ltd (Switzerland), Getinge AB. (Sweden), LivaNova PLC (U.K.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd (India), Terumo Medical Corporation (U.S.), WEINMANN Emergency Medical Technology GmbH + Co. KG (Germany), among others.

Q.5. Which region is estimated to held highest CAGR inacute respiratory distress syndrome (ARDS)market?

North America is estimated to hold biggest share in the market for acute respiratory distress syndrome (ARDS).